CMS Adds Veltassa to CY16 Formulary Reference File; H.C. Wainwright Affirms Relypsa (RLYP) at 'Buy'
Get Alerts RLYP Hot Sheet
Rating Summary:
3 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 36
Join SI Premium – FREE
H.C. Wainwright affirmed Relypsa, Inc. (Nasdaq: RLYP) with a Buy rating and $63 price target after the Centers for Medicare & Medicaid Service added Veltassa to its calendar year 2016 Formulary Reference File on Thursday.
Analyst Ed Arce noted that the current FRF includes all three dosage strength of Veltassa listed on the label (8.4, 16.8, and 25.5 gram patiromer packets). The analyst views the decision by CMS as both positive and early, with initail expectations calling for a March decision. The decision will allow for reimbursement to Medicare Part D prescription drug plans (PDPs) that adopt Veltassa on formulary.
Arce said that, according to the Kaiser Family Foundation, there are 886 PDPs available in CY16 and Relypsa sees about 60 percent of the 3 million-plus Veltassa-eligable patient population being covered by Medicare.
For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Intrum AB (INTRUM:SS) to Underweight 'Following the appointment of Houlihan Lokey and Milbank as advisors'
- Guggenheim Starts Globant S.A. (GLOB) at Buy
- Wells Fargo Downgrades Nuscale Power (SMR) to Underweight, 'Behind the Eight Ball'
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!